💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Hydroxyurea

CHEMBL467 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
76.1 g/mol
LogP
-1.8
Phase
4

This oral chemotherapy drug works by inhibiting an enzyme called ribonucleotide reductase, slowing the growth of rapidly dividing cells. It is used to treat sickle cell disease (by increasing fetal hemoglobin), certain leukemias, and polycythemia vera. Regular blood count monitoring is essential during treatment.

Молекулярная масса

76,0550 g/mol

LogP

-1,80

TPSA

75,40 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Multiple Sclerosis Chronic Kidney Disease Stroke Lymphoma Hypertension Breast Cancer Chronic Pain Malaria HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
NC(=O)NO

                

                

                
                

                    
InChI

                    
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

                

                

                

                    
                    

                        
Molecular Formula

                        
CH4N2O2

                    

                    
                    

                        
HBD / HBA

                        
3 / 2

                    

                    
                    

                        
Вращаемые Связи

                        
0

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
5

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This oral chemotherapy drug works by inhibiting an enzyme called ribonucleotide reductase, slowing the growth of rapidly dividing cells. It is used to treat sickle cell disease (by increasing fetal hemoglobin), certain leukemias, and polycythemia vera. Regular blood count monitoring is essential during treatment.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Hydroxyurea is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL467.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3657.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.